Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 210563
Company: PHARMACYCLICS INC
Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
IMBRUVICA IBRUTINIB 140MG TABLET;ORAL Prescription None Yes No
IMBRUVICA IBRUTINIB 280MG TABLET;ORAL Prescription None Yes No
IMBRUVICA IBRUTINIB 420MG TABLET;ORAL Prescription None Yes No
IMBRUVICA IBRUTINIB 560MG TABLET;ORAL Prescription None Yes Yes
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
02/16/2018 ORIG-2 Approval Efficacy PRIORITY; Orphan Label (PDF)
Review
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210563-orig2lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210563Orig1s000,210563Orig2s000TOC.cfm
02/16/2018 ORIG-1 Approval Type 3 - New Dosage Form PRIORITY; Orphan Label (PDF)
Letter (PDF)
Review
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210563s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210563Orig2s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210563Orig1s000,210563Orig2s000TOC.cfm
Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
11/21/2019 SUPPL-4 Labeling-Package Insert Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205552s029,210563s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/205552Orig1s029, 210563Orig1s004ltr.pdf
07/15/2019 SUPPL-3 Labeling-Package Insert Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205552s028,210563s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/205552Orig1s028, 210563Orig1s003ltr.pdf
01/25/2019 SUPPL-2 Efficacy-Labeling Change With Clinical Data Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205552s026,210563s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/205552Orig1s026,210563Orig1s002Ltr.pdf
08/24/2018 SUPPL-1 Efficacy-New Dosing Regimen Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210563s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/205552Orig1s024,210563Orig1s001ltr.pdf
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
11/21/2019 SUPPL-4 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205552s029,210563s004lbl.pdf
07/15/2019 SUPPL-3 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205552s028,210563s003lbl.pdf
01/25/2019 SUPPL-2 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205552s026,210563s002lbl.pdf
08/24/2018 SUPPL-1 Efficacy-New Dosing Regimen Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210563s001lbl.pdf
02/16/2018 ORIG-2 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210563-orig2lbl.pdf
02/16/2018 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210563s000lbl.pdf

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English